Anonymous
Guest
Anonymous
Guest
High dose generic too. Two lower strengths go generic next Feb now the high dose goes. At least we have Tekturna.
Actavis Confirms Generic Exelon Patch Patent Challenge; Innopharma Debuts Generic Vistide in USA
Actavis (formerly trading as Watson) filed an amendment to its abbreviated new drug application (ANDA) for rivastigmine transdermal system to include the 13.3mg per 24 hours dosage strength. The company’s ANDA product is a generic version of Novartis’ Exelon Patch, a prescription medicine used to treat people with mild-to-moderate dementia associated with Alzheimer’s disease (AD) or Parkinson’s disease. Earlier, the company had filed an ANDA with the US Food and Drug Administration requesting the approval to market the rivastigmine transdermal system patch 4.6mg/24 hr and 9.5mg/24 hr. Further, on March 7, 2013, Novartis filed a suit against Watson in the US District Court for the District of Delaware requesting to prevent Actavis from commercializing its 13.3mg/ 24-hour strength product prior to the expiration of certain US patents.
The Pharma Letter, © 2013 thepharmaletter.com March 09, 2013
Actavis Confirms Generic Exelon Patch Patent Challenge; Innopharma Debuts Generic Vistide in USA
Actavis (formerly trading as Watson) filed an amendment to its abbreviated new drug application (ANDA) for rivastigmine transdermal system to include the 13.3mg per 24 hours dosage strength. The company’s ANDA product is a generic version of Novartis’ Exelon Patch, a prescription medicine used to treat people with mild-to-moderate dementia associated with Alzheimer’s disease (AD) or Parkinson’s disease. Earlier, the company had filed an ANDA with the US Food and Drug Administration requesting the approval to market the rivastigmine transdermal system patch 4.6mg/24 hr and 9.5mg/24 hr. Further, on March 7, 2013, Novartis filed a suit against Watson in the US District Court for the District of Delaware requesting to prevent Actavis from commercializing its 13.3mg/ 24-hour strength product prior to the expiration of certain US patents.
The Pharma Letter, © 2013 thepharmaletter.com March 09, 2013